Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
NCT01366209 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2011
- Completion date
- February 28, 2014
- Enrollment
- 555 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.